3SOF

Nice lalitha0!
you did better than me..i sold half my shares at .005...i actually had tried to cancel my sell order wehn i saw it moivng..but,it was too late..it got eaten...but, at least i am still riding free shares..so all in all..its been a good day for me finally

Well..excpet literally all my other stocks except 2 have dropped signifcantly..but, i'm just trying to enjoy OXFV today!! And i am!!!

good luck to everyone...i have no idea how this is goiing or if it will contiue tomorrow..right now though it looks very strong...may sell half of my remaining half at some point today..and see if tomorrow continues...never know...rnvo...nnnc....could oxfv be related to them in its movements...i hope so!!!


good luck everyone....DAVID....I hope u held on and didn't sell it all at 20%...I know u have a plan...but, sometimes, a quick adjustment can be good too!!!

julia

Well I never played this one but wished David did not sell it. Sometimes these penny pauppers make you millionaire in a blink of a day.

Well done David and 3SF. This guy needs more then applauds. Three cheers and a hurrah!

I am assuming tomorrow its going to be HYRF day. Just dont sell your shares cheap. I may buy more if the stock does not gap open much.

Hi David,

Thank you for a great stock pick!! APPLAUD!! APPLAUD!! 

( How do I insert Applaud?)

Sorry about the way it all got started, but at least we didn't lose money.

I know that is not as important as staying disciplined.

I see that you sold it at 20% gain as planned. I do applaud your discipline!

Now that the news is out I was wondering what you would do if the stock came up on your

screener today based on todays exceptional performance of OXFV!

Would you decide to buy in tomorrow if there is some pull back? or the day after?

Thanks,

Lalitha

Hello 

As I see it the hedge funds that provided the capital for all the transactions the company made are selling shares while there is demand for the stock.

I put a sell order at $0.0035 and went away, but what an amazing day yesterday, this could have been a 3 bagger for me instead of just 20%. Well, it was better than losing, thanks for warning me of that merger hidden on the SEC filing lalitha, whitout you it would have been harder to hold the stock.

That 10 day moratorium on selling was wise, it gave me time to learn more about the company and perceive its short term potential.

But now I wouldn't touch it for some time ... some months to come.

Thank you David.

Julia,

I was wondering what you are doing with this stock. I kept some shares in case over the weekend some people will see the action from yesterday and since it pulled back a lot today might get in Monday or tuesday.

Thanks.
Lalitha

NEWS TODAY:

ULURU Formed to Develop Innovative Oral and Topical Products; Commercialization Strategy Focused on Wound Management, Burn Care and Products for Facial Restoration
Business Wire - October 28, 2005 10:42

DALLAS, Oct 28, 2005 (BUSINESS WIRE) -- ULURU INC. ("ULURU"), is an emerging pharmaceutical company focused on the development of a portfolio of innovative topical delivery technologies to provide patients and consumers with an improved clinical outcome through controlled delivery. ULURU was formed to acquire the topical assets of Access Pharmaceuticals, Inc. and subsequently merge with Oxford Ventures, Inc. (OTC bulletin board: OXFV). The companies have now entered a definitive merger agreement.

ULURU plans to establish a commercial organization to market products in niche areas including wound management, burn care and facial restoration and plans to out-license products that fall outside the strategic focus of the commercial organization. Commercial partners will be sought to market all products in international markets.

The focus of our development and commercial activities with the nanoparticle aggregate technology is in three market segments, wound management, burn care and dermal fillers for facial restoration. These markets are currently projected to exceed $3 billion and are projected to expand substantially over the next five years. The technology development focus for wound management and burn care is directed towards producing protective film barrier dressings that will release drugs including antibiotics and pain medications. Innovative products in the wound management and burn care categories which can deliver drugs and require significantly less nursing care offer exciting potential.

The dermal filler market is a rapidly expanding category where currently available products degrade in a relatively short period requiring repeat procedures. A significant opportunity exists to develop a permanent sub-dermal filler to address the deep tissue problems associated with facial restoration. Developing such a product is ULURU's focus, which presents us with a unique opportunity to lead the development of a market segment which we project will expand into a market that exceeds $500 million.

As part of the acquisition of the topical product assets of Access Pharamceuticals, Inc., the strategic partnerships associated with the acquired technologies were transferred to ULURU. An extensive network of licenses is in place to globally market our approved products, these alliances include:

Product                    Partner                 Territory
    -------                    -------                 ---------
OraDisc- Benzocaine   Wyeth Consumer Healthcare       North America
OraDisc- Amlexanox          Discus Dental             United States
                               Zambon                    Europe
                               Esteve          Spain, Portugal, Greece
                               Meda AB                Scandinavia
                             ProStrakan                UK Ireland
                               EpiTan          Australia / New Zealand
                           Orient Europharma              Asia

In addition ULURU's product Zindaclin, a once daily treatment for acne, has been licensed worldwide to ProStrakan. In turn, ProStrakan has established an extensive network of sub-licensees to market the product globally, including Fujisawa, for certain European markets, Pliva for the Central Eastern Europe region and numerous additional licensees for smaller territories.

The licenses currently in place provide ULURU with licensing revenue on the achievement of certain development and commercial milestones of in excess of $15 million. Additionally, ULURU will receive royalty payments in the range of 5-15% on all worldwide sales.

In addition to ULURU's current OraDisc products, amlexanox for the prevention and treatment of canker sores and benzocaine for oral pain, ULURU has prioritized tooth whitening, cough and cold and desensitizing teeth as the lead consumer product developments. Also, ULURU plans to develop a range of prescription products utilizing OraDisc as a transmucosal delivery device. Supportive cancer care products and migraine relief are the initial development focus.

Commenting on the status of the company, Kerry P. Gray President and CEO of ULURU stated, "Establishing a commercial operation centered on our innovative nanoparticle aggregate technology, which presents us with the opportunity to market numerous products to meet unmet medical needs, is an exciting opportunity. We anticipate that we will continue to expand our network of strategic partners. We are currently working with a number of major pharmaceutical companies who are evaluating our technology and conducting consumer market research. Utilizing our technology portfolio, we believe it is possible to rapidly and cost-effectively develop value-added products. Given the numerous applications of the technology, we believe that we have the opportunity to significantly increase revenue from licensing activities."

ULURU Inc. is an emerging, specialty pharmaceutical company focused on the development of a portfolio of topical delivery technologies to proved patients and consumers with an improved clinical outcome through controlled delivery utilizing its innovative transmucosal delivery system and hydrogel nanoparticle aggregate technology.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and involve risks and uncertainties, including but not limited to statements made relating to the business prospects of ULURU Inc., the potential for ULURU Inc. to secure and maintain strategic partners, licensing revenues to be received under existing agreements and development of product candidates. These statements are subject to numerous risks and uncertainties.

SOURCE: ULURU Inc.

ULURU Inc.
Kerry P. Gray, 214-905-5145
President & CEO

LALITHA

And this news just out as well....


ULURU Awarded a U.S. Army Small Business Innovative Research Grant; Grant to Support the Development of a Wound Dressing for Burns
11/1/2005 12:18:01 PM



DALLAS, Nov 01, 2005 (BUSINESS WIRE) -- ULURU INC. ("ULURU") who has signed a definitive merger agreement with Oxford Ventures, Inc. (OXFV) today announced the award of a U.S. Army Small Business Innovative Research ("SBIR") Grant.







The U.S. Army SBIR Program has competitively selected a proposal that utilizes ULURU's Hydrogel Nanoparticle Aggregate Technology for award and contract negotiation. The objective of the SBIR proposal solicitation, topic number A05-131, was to design and manufacture a wound dressing that can be placed over burns to enhance the rate of wound closure. Such a dressing should be capable of absorbing wound fluids, speed up the rate of wound healing, require few dressing changes (e.g. can be left in place for up to seven days), provide antibacterial action, deliver nutritive substances, have a long shelf life (e.g. one year) and not require special storage conditions (e.g. freezing).

We believe that ULURU's Hydrogel Nanoparticle Aggregate Technology is well suited for wound healing as it is designed to modify the biochemical environment of a wound in order to maintain an optimum moisture balance with concomitant drug release and has the necessary properties to achieve the design features outlined in the U.S. Army SBIR proposal. Utilizing our innovative Hydrogel Nanoparticle Aggregate topical delivery technology for development of an advanced burn care product outlined in this SBIR is a primary focus of our burn care and wound management product portfolio. ULURU is striving to develop in vitro and in vivo proof-of-concept experiments as specified in the Phase I objectives of the SBIR proposal. To date, we are showing promising results for the improved treatment of burns.

ULURU is applying for up to a $1 million fast-track Phase II SBIR funding to develop and demonstrate the efficacy of a prototype wound dressing and move into human clinical trials. By improving treatment to return damaged skin to optimal appearance and normal function in the shortest time, we anticipate that this wound dressing could be used in a broad range of military and civilian medical settings and may benefit many military and civilian patients suffering from chronic vesicant injuries.

Commenting on the SBIR award Kerry P. Gray, President and CEO of ULURU stated, "This is an important scientific validation of our Hydrogel Nanoparticle Aggregate Technology for the development of burn and wound management products. We look forward to working with the Army to optimize a burn care product for military use."

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of topical delivery technologies to provide patients and consumers with an improved clinical outcome through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate Technology.

SOURCE: ULURU Inc.

ULURU Inc.
Kerry P. Gray, 214-905-5145

Hi Julia,

Are you still in OXFV?

I am keeping some for the long term. I think there is future in this.

I was wondering what other penny stocks you have. I am getting more and more into penny stocks and I think it is exciting to find them.

Do you have nnvc.pk? Now it just went up over a dollar and closed at $1 today.

Thanks,

Lalitha